Package Leaflet: Information for the User
ALPROLIX 250UI powder and solvent for solution for injection
ALPROLIX 500UI powder and solvent for solution for injection
ALPROLIX 1000UI powder and solvent for solution for injection
ALPROLIX 2000UI powder and solvent for solution for injection
ALPROLIX 3000UI powder and solvent for solution for injection
eftrenonacog alfa recombinant coagulation factor IX, Fc fusion protein
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
ALPROLIX contains the active substance eftrenonacog alfa, a recombinant coagulation factor IX, Fc fusion protein. Factor IX is a protein that is naturally produced by the body and is necessary for blood to form clots and stop bleeding.
ALPROLIX is a medicine used to treat and prevent bleeding in patients of all ages with hemophilia B (a hereditary bleeding disorder caused by a deficiency of factor IX).
ALPROLIX is prepared using recombinant technology without the addition of any human or animal component in the manufacturing process.
How ALPROLIX works
In patients with hemophilia B, factor IX is missing or does not work properly. This medicine is used to replace the missing or deficient factor IX. ALPROLIX increases factor IX concentrations in the blood and temporarily corrects the tendency to bleed. The Fc fusion protein in this medicine prolongs the duration of action of the medicine.
Do not use ALPROLIX
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using ALPROLIX.
Patient with a factor IX inhibitor may have a higher risk of anaphylaxis during future treatments with factor IX. Therefore, if you experience allergic reactions such as those described above, you should be tested for the presence of an inhibitor.
Factor IX medicines may increase the risk of unwanted blood clots in your body, especially if you have risk factors for developing blood clots. Symptoms of a possible unwanted blood clot may include: pain and/or tenderness along a vein, unexpected swelling of an arm or leg, or sudden shortness of breath or difficulty breathing.
Cardiovascular disorders
If you have been told that you have a heart condition or are at risk of having one, be extra careful when using factor IX and talk to your doctor.
Catheter-related complications
If you need a central venous access device (CVAD), you should be aware of the risk of CVAD-related complications, including local infections, bacteria in the blood, and blood clots at the catheter insertion site.
Documentation
We strongly recommend that every time ALPROLIX is administered, the name and batch number of the product are recorded.
Other medicines and ALPROLIX
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Driving and using machines
ALPROLIX has no influence on the ability to drive and use machines.
ALPROLIX contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per vial, i.e., it is essentially “sodium-free”. In case of treatment with several vials, the total sodium content should be taken into account.
Treatment with ALPROLIX will be started by a doctor who is experienced in the care of patients with hemophilia. Follow exactly the administration instructions of this medicine given by your doctor (see section 7). If you are unsure, talk to your doctor, pharmacist, or nurse.
ALPROLIX is given by injection into a vein. You or another person can administer it after receiving the necessary training. Your doctor will decide the dose (in International Units or “IU”) that you will receive. The dose will depend on your individual needs for factor IX replacement treatment and whether it is used for prevention or treatment of bleeding. Talk to your doctor if you think you are not getting control of bleeding with the dose you are receiving.
How often you will need an injection will depend on how well the medicine is working for you. Your doctor will perform the relevant laboratory tests to ensure that you have adequate factor IX concentrations in the blood.
Treatment of bleeding
The dose of ALPROLIX is calculated based on your body weight and the desired factor IX concentrations. The target factor IX concentrations depend on the severity and location of the bleeding.
Prevention of bleeding
If you are using ALPROLIX to prevent bleeding, your doctor will calculate the dose.
The usual dose of ALPROLIX is 50 IU per kilogram of body weight, administered once a week, or 100 IU per kilogram of body weight, administered once every 10 days. Your doctor may adjust the dose or interval. In some cases, especially in younger patients, shorter dosing intervals or higher doses may be necessary.
Use in children and adolescents
ALPROLIX can be used in children and adolescents of all ages. In children under 12 years, higher doses or more frequent injections may be necessary, and the usual dose is 50 to 60 IU per kilogram of body weight, administered once every 7 days.
If you use more ALPROLIX than you should
Tell your doctor as soon as possible. Follow exactly the administration instructions of ALPROLIX given by your doctor. If you are unsure, talk to your doctor, pharmacist, or nurse.
If you forget to use ALPROLIX
Do not take a double dose to make up for forgotten doses. Take your dose as soon as you remember and then continue with your normal dosing schedule. If you are unsure, talk to your doctor, pharmacist, or nurse.
If you stop using ALPROLIX
Do not stop using ALPROLIX without talking to your doctor. If you stop using ALPROLIX, you may no longer be protected against bleeding or an existing bleed may not stop.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If a severe allergic reaction (anaphylactic reaction) occurs, the injection should be stopped immediately. You should contact your doctor immediately if you experience any of the following symptoms of allergic reactions: swelling of the face, rash, generalized itching, hives, tightness in the chest, difficulty breathing, and low blood pressure.
In children who have not received previous treatment with factor IX-containing medicines, it is common for inhibitors to form (in up to 1 in 10 patients) (see section 2). If this happens, the medicine may stop working properly, and your child may experience persistent bleeding. If this happens, you should contact your doctor immediately.
The following side effects may occur with this medicine.
Common side effects (may affect up to 1 in 10 people):headache, numbness or tingling in the mouth, pain in the side with blood in the urine (obstructive uropathy), and redness at the injection site.
Children who have not received previous treatment with factor IX-containing medicines: factor IX inhibitors, hypersensitivity.
Uncommon side effects (may affect up to 1 in 100 people):dizziness, altered taste, bad breath, feeling tired, pain at the injection site, rapid heartbeat, blood in the urine (hematuria), pain in the side (renal colic), low blood pressure, and decreased appetite.
Rare side effects (frequency cannot be estimated from the available data):severe allergic reaction and potentially life-threatening allergic reaction (anaphylactic shock).
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on the label of the vial after “EXP”. The expiry date refers to the last day of the month stated. Do not use this medicine if it has been stored at room temperature for more than 6 months.
Store in a refrigerator (between 2°C - 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light.
Alternatively, ALPROLIX can be stored at room temperature (up to 30°C) for a single period not exceeding 6 months. Record the date when you removed ALPROLIX from the refrigerator and stored it at room temperature on the carton. After storage at room temperature, the medicine should not be put back in the refrigerator.
Once you have prepared ALPROLIX, you should use it immediately. If you cannot use the prepared solution immediately, you should use it within 6 hours if it has been stored at room temperature. Do not refrigerate the solution after preparation. Protect the solution from direct sunlight.
The prepared solution should be clear to slightly pearlescent (opalescent) and colorless. Do not use this medicine if you notice that it is cloudy or contains visible particles.
This medicine is for single use only.
Dispose of any unused solution properly. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
ALPROLIX Composition
Powder:
Solvent:
5 ml of sodium chloride and water for injections
Product Appearance and Container Contents
ALPROLIX is presented as a powder and solvent for solution for injection. The powder is a white to off-white powder or cake. The solvent supplied for the preparation of the solution is a clear and colorless solution. After preparation, the solution is clear to slightly opalescent and colorless.
Each ALPROLIX container contains 1 vial of powder, 5 ml of solvent in a prefilled syringe, 1 plunger rod, 1 vial adapter, 1 infusion set, 2 alcohol swabs, 2 bandages, and 1 gauze.
Marketing Authorization Holder and Manufacturer
Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm
Sweden
Phone: +46 8 697 20 00
Date of Last Revision of this Leaflet: 01/2024
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.
Turn the leaflet over to read section 7. Preparation and Administration Instructions
The following procedure describes the preparation and administration of ALPROLIX.
ALPROLIX is administered by intravenous (IV) injection after dissolving the injectable powder with the solvent supplied in the prefilled syringe. The ALPROLIX container contains:
ALPROLIX must not be mixed with other injectable solutions or infusions.
Wash your hands before opening the container.
Preparation:
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
Do not shake. | |
| |
Note: If using more than one vial of ALPROLIX per injection, each vial must be prepared separately according to the previous instructions (steps 1 to 13) and the solvent syringe must be removed, leaving the vial adapter in place. A single larger luer lock syringe may be used to withdraw the prepared contents from each of the vials. | |
| |
Note: If the solution is not to be used immediately, the syringe cap should be carefully replaced over the syringe tip. Do not touch the syringe tip or the inside of the cap. After preparation, ALPROLIX can be stored at room temperature for a maximum of 6 hours before administration. After this time, the prepared ALPROLIX solution must be discarded. Protect it from direct sunlight. |
Administration (Intravenous Injection):
ALPROLIX should be administered using the infusion set (E) provided in the container.
| |
| |
| |
| |
| |
|